Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This double-blind, 12-week study will consist include132 anxious youth who are randomized
(1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization
(1:1) will be stratified by sex and metabolizer status.
Phase:
Phase 4
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)